Icon Back Back to Search Results

Diagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer

  • Recruiting
  • Observational
  • Heinrich-Heine University, Duesseldorf
  • 18 Years -

Study Purpose

Following numerous retrospective studies and Phase-3-Studies with promising results, \[18F\]PSMA-1007 has been approved by european authorities. Therefore, it is a growing deployment of this diagnostic method anticipated. This study aims to investigate the diagnostic performance and clinical impact in a real-world-evidence in the context of regular clinical care. The evidence generated by this approach is supposed to assist in optimizing the management of prostate cancer patients.

Intervention

N/A

Eligibility Requirements

info icon Informed Consent

info icon Conduct of \[18F\]PSMA-1007 PET Imaging in the context of regular clinical care

info icon Minimum age: 18

info icon Technical Flaws in the acquisition protocol

Recruiting status

Recruiting

Estimated enrollment

250

 
Study start date

Nov 01, 2024

Study end date

Nov 30, 2028

Last updated

Mar 24, 2025

Primary purpose

N/A

Design

Observational

Intervention

Study phase

N/A

Allocation

N/A

 

Sponsor:

Heinrich-Heine University, Duesseldorf

Collaborator:

N/A

Investigator:

Frederik Lars Giesel, Prof. Dr., Medical Doctor

N/A

NCT06657131

Clinic Location Investigator Distance RECRUITING STATUS Contact